<DOC>
	<DOCNO>NCT01870557</DOCNO>
	<brief_summary>Objective To collate bone status type 1 type 2 diabetic use biochemical marker bone scan . Methods : This multicenter trial involve University Hospitals three major danish city : Aalborg , Aarhus Odense . The trial cross-sectional design consist examination include : - Blood sample analyze bone marker , glycemic state , kidney function sex-hormones . - 24 hour urine sample analyze bone marker kidney function . - Bone scan include dual energy x-ray absorptiometry ( DXA ) high resolution peripheral quantitative compute tomography ( HRpQCT ) evaluate Bone Mineral Density , t-score bone structure . Participants : 100 type 1 diabetic 100 type 2 diabetic recruit outpatient clinic Aalborg , Aarhus Odense , general practitioner flyer .</brief_summary>
	<brief_title>Markers Bone Status Diabetes Mellitus ( Type 1 Type 2 )</brief_title>
	<detailed_description>Diabetes Mellitus Osteoporosis common condition . Patients Diabetes Mellitus know fracture non-diabetic counterpart . However bone mineral density ( BMD ) commonly use measure fracture risk seem insensitive diabetes , thus BMD lower type 1 diabetes enough explain almost seven fold fracture risk . BMD increase type 2 diabetes although still increase fracture risk . The investigator investigate paradox diabetes assess type 1 type 2 diabetes patient bone status blood- urine sample ( assess marker bone- glycemic state ) two type bone scan comprise DXA HRpQCT scan . The diabetes mellitus patient recruit outpatient clinic three study site ( Aalborg , Aarhus Odense ) well general practitioner flyer add .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Bone Diseases , Metabolic</mesh_term>
	<criteria>Type 1 type 2 diabetes . Age ≥ 50 year . Unaltered treatment diabetes previous six month ( change drug , increase decrease dose accept ) HbA1c stable level ± 1 period . HbA1c level≥ 7 % previous six month . BMI 19 og 35 . Specific inclusion criterion type 2 diabetes : Either treatment metformin , sulfonylurea , dipeptidyl peptidase IV ( DPP IV ) inhibitor glucagonlike peptide 1 ( GLP1 ) analog . Treatment insulin insulin combination metformin , sulfonylurea , DPP IV inhibitor GLP1 analog . HbA1C &gt; 10 % Pregnancy . Metal implant ankle wrist . Patients treat : Antiresorptive ( incl . hormone replacement therapy ) bone anabolic treatment , glucocorticoid , lithium anticonvulsives . Patients bone disease osteoporosis . Vertebral fracture visible vertebral fracture assessment ( VFA ) . Patients renal disease define estimate glomerular filtration rate ( eGFR ) &lt; 50 . Other medical disease unstable phase ( fx . cancer , hyperthyroidism ) . Heart failure ; New York Heart Association ( NYHA ) class IV . Patients investigator believe fit participate study</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Bone</keyword>
	<keyword>Bone Status</keyword>
	<keyword>Glycemic Markers</keyword>
	<keyword>Osteoporosis</keyword>
	<keyword>Osteopenia</keyword>
</DOC>